<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Apenteng, Patricia N</style></author><author><style face="normal" font="default" size="100%">Virdone, Saverio</style></author><author><style face="normal" font="default" size="100%">Hobbs, FD Richard</style></author><author><style face="normal" font="default" size="100%">Camm, A John</style></author><author><style face="normal" font="default" size="100%">Fox, Keith AA</style></author><author><style face="normal" font="default" size="100%">Pieper, Karen S</style></author><author><style face="normal" font="default" size="100%">Kayani, Gloria</style></author><author><style face="normal" font="default" size="100%">Fitzmaurice, David</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">,</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of General Practice</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">e693-e701</style></pages><doi><style  face="normal" font="default" size="100%">10.3399/BJGP.2021.0548</style></doi><volume><style face="normal" font="default" size="100%">72</style></volume><issue><style face="normal" font="default" size="100%">723</style></issue><abstract><style  face="normal" font="default" size="100%">Background The outcomes of patients newly diagnosed with atrial fibrillation (AF) following the introduction of direct-acting oral anticoagulants are not well known.Aim To determine the 2-year outcomes of patients newly diagnosed with AF, and the effectiveness of oral anticoagulants in everyday practice.Design and setting This was a prospective observational cohort study in UK primary care.Method In total, 3574 patients aged ≥18 years with a new AF diagnosis were enrolled. A propensity score was applied using an overlap weighting scheme to obtain unbiased estimates of the treatment effect of anticoagulation versus no anticoagulation on the occurrence of death, non-haemorrhagic stroke/systemic embolism, and major bleeding within 2 years of diagnosis.Results Overall, 65.8% received anticoagulant therapy, 20.8% received an antiplatelet only, and 13.4% received neither. During the study period, the overall incidence rates of all-cause mortality, non-haemorrhagic stroke/systemic embolism, and major bleeding were 4.15 (95% confidence interval [CI] = 3.69 to 4.65), 1.45 (95% CI = 1.19 to 1.77), and 1.21 (95% CI = 0.97 to 1.50) per 100 person–years, respectively. Anticoagulation treatment compared with no anticoagulation treatment was associated with significantly lower all-cause mortality adjusted hazard ratio (aHR) 0.70 (95% CI = 0.53 to 0.93), significantly lower risk of non-haemorrhagic stroke/systemic embolism (aHR 0.39, 95% CI = 0.24 to 0.62), and a non-significant higher risk of major bleeding (aHR 1.31, 95% CI = 0.77 to 2.24).Conclusion The data support a benefit of anticoagulation in reducing stroke and death, without an increased risk of a major bleed in patients with new-onset AF. Anticoagulation treatment in patients at high risk of stroke who are not receiving anticoagulation may further improve outcomes.</style></abstract></record></records></xml>